STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2018

Oct 31, 2018

==> picture [129 x 54] intentionally omitted <==

October 31, 2018

BSE Limited

Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip code: 532531

The National Stock Exchange of India Limited Exchange Plaza , Bandra-Kurla Complex Bandra (E) Mumbai - 400 051

Scrip code: STAR

Dear Sirs,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

“Strides partners with ICP-III Investment Advisors to fund its nascent Consumer Health Care business”

Also, enclosed is the disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 on the said transaction.

Thanks & Regards,

For Strides Pharma Science Limited

==> picture [135 x 55] intentionally omitted <==

Manjula Ramamurthy Company Secretary

==> picture [89 x 88] intentionally omitted <==

Encl: As Above

Strides Pharma Science Limited (Formerly Strides Shasun Limited) CIN: L24230MH1990PLC057062 Corp Off : Strides House, Bilekahalli, Bannerghatta Road, Bangalore - 560 076, India Tel: +91 80 6784 0000 Fax: +91 80 6784 0700 Regd Off : 201, Devavrata, Sector 17, Vashi, Navi Mumbai – 400 703, India Tel: +91 22 2789 2924 / 3199 Fax: +91 22 2789 2942 info@strides.com; www.strides.com

Press Release

Strides partners with ICP‐III Investment Advisors to fund its nascent Consumer Health Care business

Investor to infuse USD 20 Million to fund growth

Bangalore, October 31, 2018

Strides Pharma Science Limited (Strides) today announced that its board of directors have approved the execution by Strides of definitive agreements with funds advised by ICP‐III Investment Advisors (ICP) to provide growth capital and focused attention to its Consumer Healthcare Business (CHC). ICP would provide the business with a USD 20 Million capital for growth. The CHC business comprises of key brands including JointFlex®, Pediacare®, NiteThru™ and NixIt™ sold across key regulated and emerging markets. The business had Revenues of USD 6.4 Million for FY18.

The proposed transaction will be subject to customary closing conditions.

Key Terms

• The proposed transaction involves subscribing to the equity capital of Strides Consumer Pvt Ltd, India (SCPL) and Strides Global Consumer Healthcare Ltd, UK (SGCHL), which are currently wholly owned subsidiaries of the Company.

• The agreement also envisages SCPL to become a fully owned subsidiary of SGCHL, UK at a later date, subject to approval of Reserve Bank of India.

For Strides, MAPE Advisory Group acted as the transaction advisor.

About Strides CHC business

Strides CHC business currently operates key brands of JointFlex®, Pediacare®, NiteThru™ and NixIt™ in USA, India and other geographies globally, in Consumer Healthcare categories of smoking cessation, oral and topical analgesic, sleep aids and products for pediatric care.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is global pharmaceutical Company headquartered in Bangalore. The Company has two business verticals, viz., Regulated Markets and Emerging Markets. The Company has a global manufacturing footprint with 7 manufacturing facilities spread across three continents including 5 Regulated market facilities and 2 facilities for the emerging markets. The Company has strong R&D infrastructure in India with global filing capabilities and a strong commercial footprint across 100 countries. Additional information is available at the Company’s website at www.strides.com

For further information, please contact:

StridesBadree Komandur,Executive Director ‐ Finance+91 80 6784 0747Investor Relations:Kannan. N: +91 98450 54745Vikesh Kumar: +91 80 6784 0827Sandeep Baid : +91 80 6784 0791Strides Pharma Science Limited(Formerly Strides Shasun Limited)CIN : L24230MH1990PLC057062Regd. Office: 201, ‘Devavrata’, Sector ‐ 17,Vashi, Navi Mumbai ‐ 400 703Corp. Office: Strides House,Bannerghatta Road, Bangalore ‐ 560076Email: investors@strides.com		PR ConsultancyFortuna PRK Srinivas Reddy: +91 90005 27213srinivas@fortunapr.com K Priya: +91 95354 25418priya@fortunapr.com

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sale or disposal of unit(s) or division(s) or subsidiary of the listed entity

THE TRANSACTION IS FOR RAISING FUNDS AT SUBSIDIARY LEVEL AND NOT SALE OR DISPOSAL OF A SUBSIDIARY. AS A RESULT OF FUND RAISING AT SUBSIDIARY LEVEL, THE WHOLLY OWNED SUBSIDARIES WILL CEASE TO BE A SUBSIDIARY AND HENCE THIS DISCLOSURE IS MADE BY WAY OF ABUNDANT CAUTION.

PART A:

==> picture [470 x 523] intentionally omitted <==

----- Start of picture text ----- a) The amount and percentage of the The transaction envisages funding by way ofturnover or revenue or income and net worth direct investment by Funds advised by ICP-IIIcontributed by such unit or division of the Investment Advisors in company’s whollylisted entity during the last financial year; owned subsidiaries engaged in consumerHealth care business.At a consolidated level, CHC business had arevenue of USD 6.4 Million, which is 1.5 % ofthe turnover of the Company for financialyear ended March 31, 2018b) Date on which the business transfer Board of Directors have approved theagreement for sale has been entered ; transaction on October 31, 2018 andauthorized entering into definite agreementsc) The expected date of completion of November 30, 2018sale/disposald) Consideration to be received from such Funds advised by ICP-III Investment Advisorssale/disposal; will invest USD 20 Million in the CHC businesse) Brief details of buyers and whether any of ICP-III Investment Advisors advises fundsthe buyers belong to the promoter/ promoter which invest in industries in the LifeSciencesgroup/group companies. If yes, details sector such as Pharmaceuticals, Medicalthereof; Devices, Healthcare delivery and AnimalHealth.The Investor does not belong to thepromoter/ promoter group/ groupcompanies.f) Whether the transaction would fall within No, the transaction is not a transaction with arelated party transactions? related partyIf yes, whether the same is done at “armslength”;----- End of picture text -----

g) Additionally, in case of a slump sale, NA indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.

==> picture [90 x 87] intentionally omitted <==